The auctioning of 5G spectrum in India is now complete with Reliance Jio getting the largest piece of the pie, followed by Airtel, Vodafone Idea and Adani Data Networks. The present scenario looks very promising from various spheres be it from Indian Government point of view, Telecom providers or from subscribers’ point of view.
The future looks quite bright too – with a potential revenue of USD 17 billion by end of 2030 (as per Ericsson’s study). 5G will also enable service providers to launch new services for consumers, including home broadband, enhanced video, multiplayer mobile gaming, and AR/VR services.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
No Data Found
No Data Found
Ultima’s UG 100™, a high-throughput next-generation sequencing (NGS) instrument to generate high-quality sequencing data.
NVIDIA A30 GPUs with the NVIDIA Clara AI computing platform to perform accurate and accelerated varied level.
Ultima and NVIDIA together to develop Ultima specific germline variant pipelines for Google’s DeepVariant which can run on NVIDIA Clara™ Parabricks®
Illumina’s TruSight™ Software Suite include application of rare clinical diseases with examination of medical record and associated phenotype related to disease.
With TruSight™ (translate sequencing) Illumina has integrated its DRAGEN Bio-IT Platform, in order to enable comprehensive, streamlined variant analysis including two of its own tools, SpliceAI (splice site regions) and PrimateAI (benign missense variants)
Emedgene’s Cognitive Genomics Intelligence™ solution to produce insights for genomic data from all available resources
Collaborate together to develop technology platform for early detection of cancer.
C2i Genomics’ MRD monitoring platform, including Singaporean biotech company NovogeneAIT Genomics and NuProbe.
The C2inform assay uses patient-specific AI-based pattern recognition and error suppression methods that integrates signals for highly sensitive detection of cancer-associated DNA
India’s first AI- enabled test with trace amount of recurrent or persistent cancer.
Clinical Performance Evaluation of the C2i-Test- NCT05221827
Hematoxylin and eosin (H&E)-based Biomarker test developed by Janssen Research & Development to screen for actionable FGFR2 and FGFR3 genomic alterations.
The goal is to improve rates of confirmatory molecular testing using Paige platform, currently under evaluation on patients with advanced urothelial cancer – NCT04083976
The AI based screening simply analyse standard biopsy slides slide to spot the genetic alteration.
Focusing on artificial intelligence enabled drug discovery with its FDA approved fast track designation to AC0176 (chimeric degrader molecule targeting the androgen receptor (AR).
Currently under evaluation– NCT05241613 for the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC).
Collaborate for application of Artificial Intelligence Technology for Peptide Drug Design, building leading peptide predictive and generative modelling technology in the field of peptides.
Genius™ intelligent endoscopy module, under evaluation-for reduction in adenoma miss rate (AMR) with AI technology patient with colon cancer.
National University of Singapore (NUS), in collaboration with clinicians from the National University Cancer Institute, Singapore (NCIS), reported positive response in an artificial intelligence (AI) tool, Curate.AI, that identifies and better allows clinicians to make optimal and personalized doses of chemotherapy for patients using patient’s clinical data including drug type, drug dose and cancer biomarkers
No Data Found
No Data Found
App - 7043
Grant - 2707
App - 760
Grant - 937
App - 5700
Grant - 2738
App - 2345
Grant - 1138
No Data Found
Loading..........
The Data is Not Available
Waste water treatment is necessary to,
#59/2,Heritage Building, Kaderanahalli,Dr. Puneeth RajkumarRoad, Banashankari 2nd Stage, Bangalore 560070, Karnataka, INDIA
